We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sdi Group Plc | LSE:SDI | London | Ordinary Share | GB00B3FBWW43 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 1.82% | 56.00 | 55.00 | 57.00 | 56.00 | 55.00 | 56.00 | 87,096 | 08:00:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 67.58M | 3.87M | 0.0372 | 15.05 | 58.27M |
From Apr 2019 to Apr 2024
TIDMSDI
RNS Number : 8972U
Scientific Digital Imaging Plc
24 January 2017
Scientific Digital Imaging plc
("SDI", the "Company" or the "Group")
(AIM: SDI)
UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS TO 31 OCTOBER 2016
The Board of Scientific Digital Imaging plc, the AIM quoted group focused on the design and manufacture of scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing and art conservation markets, is pleased to announce its unaudited interim results for the six months ended 31 October 2016.
Highlights
-- Revenue increased by 33% to GBP4,902,000 (2015: GBP3,671,000) -- Profit before taxation for the period increased to GBP410,000 (2015: GBP13,000) -- Adjusted profit before taxation* for the period increased to GBP421,000 (2015: GBP173,000) -- Gross margin increased to 63.6% (2015: 58.0%) -- Sentek continued to contribute strong sales growth and profitability
-- Post period event - the acquisition of a manufacturer and supplier of chemical dosing and control systems, Astles Control Systems Limited on 12 January 2017 for an initial consideration of GBP3.446 million. At the same time, SDI announced an equity fundraising of GBP3.1 million before expenses.
* before acquisition costs, costs of reorganisation, and share based payments
Ken Ford, Chairman of SDI, commented:
"It has been a positive performance in the first half of the year, and the outlook for the full year is strong. SDI now has a growing portfolio of profitable businesses which are providing the Group with increased and sustained profitability. We have been particularly pleased with the performance of Sentek, the manufacturer of electrochemical sensors that we acquired in October 2015, and we will continue to grow as we seek to diversify our existing product range and widen our addressable market.'
Enquiries
Scientific Digital Imaging plc 01223 727144
Ken Ford, Chairman
Mike Creedon, CEO
www.scientificdigitalimaging.com
finnCap Ltd 020 7220 0500
Ed Frisby/Simon Hicks - Corporate Finance
Mia Gardner- Corporate Broking
JW Communications 07818 430877
Julia Wilson - Investor & Public Relations
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Copies of the interim report are being sent to shareholders and can also be viewed on the Company's website: www.scientificdigitalimaging.com
About SDI:
Scientific Digital Imaging plc designs and manufactures scientific and technology products for use in applications including life sciences, healthcare, astronomy, consumer manufacturing and art conservation. SDI intends to continue to grow through its own technology advancements as well as strategic, complementary acquisitions.
SDI operates through four main brands:
Synoptics
Synoptics designs and manufactures innovative systems for use in the life science and clinical markets. The Company exploits digital imaging technologies for a range of applications and offers its products through three brands:
-- Syngene - manufactures equipment for life scientists to image and analyse gels and blots used for DNA and protein analysis
-- Synbiosis - produces equipment for microbiologists to automate microbial colony counting and inhibition zone analysis
-- Synoptics Health - focuses on imaging proteins on surgical instruments in the hospital and clinical environments using the ProReveal system.
Artemis CCD
Artemis designs and manufactures sensitive cameras for deep-sky astronomical and life science imaging applications under the Atik brand.
Opus Instruments
Opus designs and manufactures Osiris, an infrared camera, which is used to examine and authenticate works of art.
Sentek
Sentek manufactures and sells both reusable and single-use electrodes for the measurement of pH and conductivity of aqueous solutions. Applications range from laboratory use, to monitoring food, beverage and biologics-based pharmaceuticals manufacturing, as well as personal care and leisure applications.
Chairman's statement
OVERVIEW
In the six-month period ended 31 October 2016, SDI has continued to successfully increase the profitability of the business.
Total revenue for the period increased by over 33% to GBP4,902,000 in the six months to 31 October 2016 (an increase of GBP1,231,000, relative to revenue of GBP3,671,000 for the six months to 31 October 2015). This increase predominantly came from Atik, Opus Instruments and Sentek with the latter becoming an important stream of revenue and profitability since being acquired in October 2015 fulfilling the Board's predicted positive impact on Group trading.
To ensure that Synoptics continues to thrive, we have appointed Dr Brian Stammers, an experienced life science expert, as CEO for Synoptics. Having worked previously with SDI through the UK Trade & Investment (UKTI) to improve the commercial success of the Synbiosis Division of Synoptics, he is reshaping the strategic direction of the Synoptics business and driving the international sales and marketing effort.
Artemis CCD also continues to report increased sales and profitability through direct and OEM camera sales.
Basic earnings per share was 0.64p (2015: 0.04p) and fully diluted earnings per share was 0.63p (2015: 0.04p).
As at 31 October 2016, the Group has net cash of GBP1,198,000 which will be used to advance SDI's own technologies as well as the acquisition of new companies with complementary technologies and it is hoped further announcements will be made in 2017 that will continue to support the expansion of the Company.
PRODUCT PORTFOLIO
Syngene, which remains the largest of the Synoptics brands, has had continued investment in order to improve software and hardware in several of its products and expects to launch new systems in 2017.
During the period, Syngene has introduced an updated version of its GeneSys image capture software. This can now acquire stain-free protein gel images and will help update the G:BOX and NuGenius systems to match the capabilities of Syngene's major competitor. North America and Asia-Pac regions remain major target markets for Syngene growth. To remain competitive in these markets a new version of the high-end G:BOX imager is being introduced in early 2017.
Synbiosis has broadened its portfolio to include additional automation for the food and clinical microbiology market. A new Minimum Inhibitory Concentration (MIC) point software module to measure antibiotic resistance has been released, which further extends the application of the ProtoCOL 3 and ChromoZona in clinical markets. This has resulted in sales growth ahead of budget. As a result of the strong worldwide drive to develop and test new antibiotics in response to increasing concerns about antimicrobic resistance, Synbiosis believes sales of its automation for this sector will continue to grow in 2017.
Synoptics Health has continued to sell ProReveal, a fluorescence test to detect proteins on re-usable surgical instruments in North American hospitals. These hospitals are using the ProReveal system to optimise the performance of their washer-disinfection process. The uptake of the test has been slower by the NHS in the UK. However, since the UK Department of Health (DoH) published additional new guidelines in July 2016 which provide the limit of acceptable protein contamination on re-usable surgical instruments (https://www.gov.uk/government/publications/management-and-decontamination-of-surgical-instruments-used-in-acute-care), there has been increased interest in ProReveal. Currently, it is the only available CE-marked instrument capable of measuring less than 50ng of protein and thus meeting DoH requirements.
During the period, Artemis CCD delivered better than expected sales and profitability. The business continues to develop market-led new products and launched the Atik 16200 camera in 2016. This high-specification CCD camera, which can be fitted to a range of telescopes, is proving popular with astronomers and there are already forward orders for the Atik 16200 which will be delivered in 2017. We continue to invest in product focused R&D and plan to bring further new products and developments to market in 2017.
The first six months have seen a significant increase in Atik sales to OEM customers. These mainly operate in the life science area where Atik cameras are used to detect end points including fluorescence and luminescence in a range of analysis techniques. Atik is able to work closely with such OEM customers bringing their experience and knowledge of low light detection to help win design-ins. We are expanding our production team in Lisbon to keep up with demand from these repeat orders and remain committed to controlling production costs. The Board expects OEM sales will continue to make a positive contribution to trading.
Opus Instruments' Osiris camera sales continue to be on budget, supported by additional sales of the Macro Lens and Illumination Kit accessories. With servicing of existing cameras and new models now being developed at our Norwich site, the Board believes the Osiris camera can be produced more cost-effectively over time. Opus is looking at ways to develop the product portfolio, including the possibility of enhanced performance versions of the existing Osiris.
Sentek reported strong growth in the first half of the year for its single-use electrode for use in bioprocessing applications. Automated systems in pharmaceuticals and biotech companies are becoming more widely used, and Sentek expects revenues from the single-use electrodes required by these systems to continue to grow. The company has been brought into the Group with no disruption and we have invested in a new website that is reaping rewards through the generation of new prospects (http://www.sentek.co.uk/).
ACQUISITIONS
SDI acquired Astles Control Systems Limited on 12 January 2017. The company, a manufacturer and supplier of chemical dosing and control systems, based in the UK, has growing revenues (five-year revenue CAGR of 17%) and is a profitable business (five-year PBT CAGR of 22%), with 70-80% of sales exported globally. The maximum consideration of GBP4.8m payable will be financed by the GBP3.1m placing, the issue of GBP100,000 in SDI shares to the vendor, GBP850,000 of existing cash as well as drawing down GBP750,000 on a new five-year term loan.
SDI is actively seeking further profitable scientific and technology acquisition targets in the GBP1m to GBP10m price range to continue its buy and build strategy.
OUTLOOK
SDI now has a growing portfolio of profitable businesses which are providing the Group with increased profitability. The Board expects the Company to continue to make good progress over the remainder of the financial year as it continues to pursue an organic and acquisitive growth strategy.
Ken Ford, Chairman
23 January 2017
Consolidated income statement
Unaudited for the six months ended 31 October 2016
Hot Features
Premium
6 months 6 months 12 months
to to to
31 October 31 October 30 April
2016 2015 2016
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
----------------------------- ----- ------------ ------------ ----------
Revenue 4,902 3,671 8,473
----------
Costs of sales (1,784) (1,541) (3,298)
----------------------------- ----- ------------ ------------ ----------
Gross Profit 3,118 2,130 5,175
----------
Administrative expenses (2,672) (1,941) (4,437)
----------------------------- ----- ------------ ------------ ----------
Adjusted operating profit 446 189 738
----------
Reorganisation costs (4) (17) (17)
----------
Share based payments (1) (4) (7)
----------
Acquisition and fundraising
costs (6) (139) (178)
----------
Operating profit 435 29 536
----------
Net financing expense (25) (16) (40)
----------------------------- ----- ------------ ------------ ----------
Profit before taxation 410 13 496
----------
Income tax credit 3 - 75
----------------------------- ----- ------------ ------------ ----------
Profit for the period 413 13 571
----------------------------- ----- ------------ ------------ ----------
Earnings per share
----------
Basic earnings per share 2 0.64p 0.04p 1.17p
----------------------------- ----- ------------ ------------ ----------
Diluted earnings per share 0.63p 0.04p 1.17p
----------------------------- ----- ------------ ------------ ----------
Consolidated statement of comprehensive income
Unaudited for the six months ended 31 October 2016
6 months 6 months 12 months
to to to
31 October 31 October 30 April
2016 2015 2016
Unaudited Unaudited Audited
GBP'000 GBP'000 GBP'000
----------------------------------------------- ------------ ------------ ----------
Profit for the period 413 13 571
----------
Other comprehensive income
Items that will be reclassified subsequently
to profit and loss
----------
Exchange differences on translating
foreign operations 218 - 82
----------------------------------------------- ------------ ------------ ----------
Total comprehensive profit for the
period 631 13 653
----------------------------------------------- ------------ ------------ ----------
Consolidated balance sheet
Unaudited at 31 October 2016
31 October 31 October 30 April
2016 2015 2016
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
------------------------------------------- ----- ----------- ----------- ---------
Assets
---------
Non-current assets
---------
Property, plant and equipment 422 367 382
Intangible assets 4,303 4,103 4,309
Deferred tax asset 76 105 67
------------------------------------------- ----- ----------- ----------- ---------
4,801 4,575 4,758
Current assets
Inventories 1,766 1,159 1,378
Trade and other receivables 1,573 1,244 1,496
Current tax assets - - 132
Cash and cash equivalents 1,773 365 1,708
------------------------------------------- ----- ----------- ----------- ---------
5,112 2,768 4,714
------------------------------------------- ----- ----------- ----------- ---------
Total assets 9,913 7,343 9,472
------------------------------------------- ----- ----------- ----------- ---------
Liabilities
---------
Current liabilities
---------
Overdraft 127 108 128
---------
Trade and other payables 1,442 1,432 1,447
---------
Provisions for warranty 21 19 18
---------
Borrowings 3 282 1,343 273
---------
Current tax payable - - 151
------------------------------------------- ----- ----------- ----------- ---------
1,872 2,902 2,017
---------
Non-current liabilities
---------
Borrowings 3 166 372 314
---------
Trade and other payables 107 73 -
---------
Deferred tax liability 373 174 377
------------------------------------------- ----- ----------- ----------- ---------
646 619 691
------------------------------------------- ----- ----------- ----------- ---------
Total liabilities 2,518 3,521 2,708
------------------------------------------- ----- ----------- ----------- ---------
Net assets 7,395 3,822 6,764
------------------------------------------- ----- ----------- ----------- ---------
Equity
---------
Share capital 642 329 642
Merger reserve 3,030 3,030 3,030
Share premium account 3,457 1,472 3,457
Foreign exchange reserve 231 (72) 13
Own shares held by Employee Benefit Trust (85) (85) (85)
Other reserves 81 80 81
Retained earnings 39 (932) (374)
------------------------------------------- ----- ----------- ----------- ---------
Total equity 7,395 3,822 6,764
------------------------------------------- ----- ----------- ----------- ---------
Consolidated statement of cash flows
Unaudited for the six months ended 31 October 2016
12 months
6 months to 6 months to to
31 October 31 October 30 April
2016 2015 2016
Unaudited Unaudited Audited
GBP'000 GBP'000 GBP'000
---------------------------------------- ------------ ------------ ----------
Operating activities
----------
Profit for the period 413 13 571
Depreciation and amortisation 354 256 663
Finance costs and income 25 16 40
Taxation expense in the income
statement - - (75)
Increase in provisions 3 1 -
Employee share based payments - 4 8
---------------------------------------- ------------ ------------ ----------
Operating cash flow before movement
in working capital 795 290 1,207
(Increase)/decrease in inventories (321) (177) (166)
Changes in trade and other receivables 133 340 421
Changes in trade and other payables 67 (48) (164)
---------------------------------------- ------------ ------------ ----------
Cash generated from operations 674 405 1,298
Interest paid (25) (16) (40)
Income taxes (received)/paid (151) 5 5
---------------------------------------- ------------ ------------ ----------
Cash generated from operating
activities 498 394 1,263
Cash flows from investing activities
Capital expenditure on fixed
assets (166) (97) (209)
Expenditure on development and
other intangibles (196) (137) (511)
Acquisition of subsidiaries,
net of cash - (2,111) (2,360)
Proceeds from sale of property,
plant and equipment - 40 65
---------------------------------------- ------------ ------------ ----------
Net cash used in investing activities (362) (2,305) (3,015)
Cash flows from financing activities
Movement in finance leases (5) (13) (21)
Share issue costs (6) -
Proceeds from share issue - 2,292
Share based payment reserve 7
Repayment of borrowings (50) (189)
Other loans (50) 100
Proceeds from bank borrowings (85) 1,253 500
---------------------------------------- ------------ ------------ ----------
Net cash from/(used in) financing
activities (140) 1,291 2,582
---------------------------------------- ------------ ------------ ----------
Net (decrease)/increase in cash
and cash equivalents (4) (620) 830
Cash and cash equivalents, beginning
of period 1,708 876 876
Foreign currency movements on
cash balances 69 1 2
---------------------------------------- ------------ ------------ ----------
Cash and cash equivalents, end
of period 1,773 257 1,708
---------------------------------------- ------------ ------------ ----------
Consolidated statement of changes in equity
Unaudited for the six months ended 31 October 2016
6 months to 31 October Own
2016 - unaudited shares
Share Merger Share held Other Foreign Retained
capital reserve premium by EBT reserves exchange earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Balance at 1 May 2016 642 3,030 3,457 (85) 81 13 (374) 6,764
Share based payments - - - - - - - -
Issue of share capital - - - - - - - -
Fundraising costs - - - - - -
Transactions with owners - - - - - - - -
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Profit for the period - - - - - - 413 413
Foreign exchange on
consolidation
of subsidiary - - - - - 218 - 218
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Total comprehensive income
for the period - - - - - 218 413 631
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Balance at 31 October 2016 642 3,030 3,457 (85) 81 231 39 7,395
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
6 months to 31 October Own
2015 - unaudited shares
Share Merger Share held Other Foreign Retained
capital reserve premium by EBT reserves exchange earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Balance at 1 May 2015 329 3,030 1,478 (85) 73 (69) (945) 3,811
Share based payments - - - - 7 - - 7
Fundraising costs - - (6) - - - - (6)
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Transactions with owners - - (6) - 7 - - 1
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Profit for the period - - - - - - 13 13
Foreign exchange on
consolidation
of subsidiary - - - - - (3) - (3)
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Total comprehensive income
for the period - - - - - (3) 13 10
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Balance at 31 October 2015 329 3,030 1,472 (85) 80 (72) (932) 3,822
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
12 months to 30 April 2016 Own
- audited shares
Share Merger Share held Other Foreign Retained
capital reserve premium by EBT reserves exchange earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Balance at 1 May 2015 329 3,030 1,478 (85) 73 (69) (945) 3,811
Shares issued 313 - 1,979 - - - - 2,292
Share based payments - - - - 8 - - 8
Transactions with owners 313 - 1,979 - 81 - - 2,300
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Profit for the year - - - - - - 571 571
---------
Foreign exchange on
consolidation
of subsidiaries - - - - - 82 - 82
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Total comprehensive income - - - - - 82 571 653
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Balance at 30 April 2016 642 3,030 3,457 (85) 81 13 (374) 6,764
--------------------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------
Notes to the interim financial statements
Unaudited for the six months ended 31 October 2016
The accompanying accounting policies and notes form an integral part of these interim financial statements.
Reporting entity
Scientific Digital Imaging plc (the "Company"), a public limited company, is the Group's ultimate parent. It is registered in England and Wales. The consolidated interim financial statements of the Company for the period ended 31 October 2016 comprise the Company and its subsidiaries (together referred to as the "Group").
Basis of preparation
The unaudited consolidated interim financial statements are for the six months ended 31 October 2016. These interim financial statements have been prepared using the recognition and measurement principles of International Accounting Standards, International Financial Reporting Standards and Interpretations adopted for use in the European Union (collectively EU IFRS). The financial information for the year ended 30 April 2016 is based upon the audited statutory accounts for that year. The consolidated interim financial information has been prepared on the historical cost basis. The consolidated interim financial statements are presented in British pounds (GBP), which is also the functional currency of the ultimate parent company.
The consolidated interim financial information was approved by the Board of Directors on 23 January 2017.
The financial information set out in this interim report does not constitute statutory accounts as defined in section 435 of the Companies Act 2006. The figures for the year ended 30 April 2016 have been extracted from the statutory financial statements of Scientific Digital Imaging plc which have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain a statement under section 498(2) or 498(3) of the Companies Act 2006. The financial information for the six months ended 31 October 2016 and for the six months ended 31 October 2015 has not been audited.
1. Principal accounting policies
The principal accounting policies adopted in the preparation of the condensed consolidated interim information are consistent with those followed in the preparation of the Group's financial statements for the year ended 30 April 2016.
The accounting policies have been applied consistently throughout the Group the purposes of preparation of these interim financial statements.
2. Earnings per share
The calculation of the basic earnings per share is based on the profits attributable to the shareholders of Scientific Digital Imaging plc divided by the weighted average number of shares in issue during the year, excluding shares held by the Synoptics Employee Benefit Trust. All profit per share calculations relate to continuing operations of the Group.
Basic
Profit Weighted earnings
attributable to average per share
shareholders number of amount in
GBP'000 shares pence
------------------------- ----------------- ----------- -----------
Period ended 31 October
2016 413 64,224,808 0.64
-----------
Period ended 31 October
2015 13 32,912,308 0.04
-----------
Year ended 30 April
2016 571 48,697,240 1.17
------------------------- ----------------- ----------- -----------
The calculation of diluted earnings per share is based on the profits attributable to the shareholders of Scientific Digital Imaging plc divided by the weighted average number of shares in issue during the year, as adjusted for dilutive share options, dilutive deferred consideration and shares held by the Synoptics Employee Benefit Trust.
Diluted
earnings
per share
amount in
pence
------------------------------ -----------
Period ended 31 October 2016 0.63
-----------
Period ended 31 October 2015 0.04
-----------
Year ended 30 April 2016 1.17
------------------------------ -----------
The reconciliation of average number of ordinary shares used for basic and diluted earnings is as below:
31 October 31 October 30 April
2016 2015 2016
------------------------------------- ----------- ----------- -----------
Weighted average number of ordinary
shares used for basic earnings
per share 64,224,808 32,912,308 48,697,240
Weighted average number of ordinary
shares under option 1,033,000 793,000 885,877
------------------------------------- ----------- ----------- -----------
Weighted average number of ordinary
shares used for diluted earnings
per share 65,257,808 33,705,308 49,583,117
------------------------------------- ----------- ----------- -----------
At 31 October 2016 206,000 share options are dilutive. At 31 October 2015 and 30 April 2016 all share options are non-dilutive. Share options could potentially dilute basic earnings per share in the future.
3. Borrowings
31 October 31 October 30 April
2016 2015 2016
GBP'000 GBP'000 GBP'000
-------------------------------- ----------- ----------- ---------
Within one year:
Bank finance 264 1,167 378
Other loan - 150 -
Finance leases 18 26 23
282 1,343 401
-------------------------------- ----------- ----------- ---------
After one year and within five
years:
Bank finance 166 367 264
Other loan - - 50
Finance leases - 5 -
-------------------------------- ----------- ----------- ---------
166 372 314
-------------------------------- ----------- ----------- ---------
Total borrowings 448 1,715 715
-------------------------------- ----------- ----------- ---------
The Group utilises short-term facilities to finance its operation. The Group has one principal banker with an invoice discounting facility of up to GBP500,000. At the end of the period the Group had utilised GBP126,902 of this facility. SDI has subsequently given NatWest notice to terminate the facility.
Scientific Digital Imaging plc
Beacon House
Nuffield Road
Cambridge
CB4 1TF
UK
Telephone: +44 (0)1223 727144 Fax: +44 (0)1223 727101 Email: info@scientificdigitalimaging.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR LLFVTLSIVFID
(END) Dow Jones Newswires
January 24, 2017 02:00 ET (07:00 GMT)
1 Year Sdi Chart |
1 Month Sdi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
